Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor

13 Dec 2022

Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.

$4 billion — Takeda will pay $4bn for Nimbus's Phase IIb TYK2 inhibitor • Source: Shutterstock

Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor

More from Deals

More from Business